Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 1

3(37.5%)

Phase 2

3(37.5%)

N/A

2(25.0%)

8Total

Phase 1(3)

Phase 2(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05846789Phase 2Recruiting

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Role: lead

NCT04134884Phase 1Completed

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Role: lead

NCT00827372Phase 2Completed

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

Role: lead

NCT02575339Phase 1Terminated

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Role: lead

NCT02595372Phase 2Completed

Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy

Role: lead

NCT03243331Phase 1Completed

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Role: lead

NCT02491957Not ApplicableCompleted

Impact of LOFT Therapy™ on Breast Cancer Survivors

Role: lead

NCT02443103Not ApplicableTerminated

Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis

Role: lead

All 8 trials loaded